Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 3,306 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,306 shares of the company’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $32.32, for a total transaction of $106,849.92. Following the completion of the sale, the insider owned 61,878 shares of the company’s stock, valued at approximately $1,999,896.96. The trade was a 5.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Down 0.1%

CSTL stock opened at $35.48 on Thursday. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $29.79 and its two-hundred day simple moving average is $25.57. Castle Biosciences, Inc. has a 1-year low of $17.72 and a 1-year high of $44.28. The stock has a market cap of $1.08 billion, a P/E ratio of -53.76 and a beta of 0.99.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.34. The firm had revenue of $99.86 million for the quarter, compared to analysts’ expectations of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. Analysts expect that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on CSTL shares. KeyCorp set a $35.00 price target on shares of Castle Biosciences in a research report on Friday, May 29th. BTIG Research raised their price objective on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Weiss Ratings upgraded shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Zacks Research downgraded Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 26th. Finally, Wall Street Zen raised Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Castle Biosciences in the second quarter valued at about $78,513,000. Summit Partners Public Asset Management LLC increased its stake in shares of Castle Biosciences by 164.7% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after purchasing an additional 658,725 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Castle Biosciences in the 2nd quarter worth approximately $15,440,000. AIGH Capital Management LLC purchased a new stake in shares of Castle Biosciences in the 2nd quarter worth approximately $13,001,000. Finally, Renaissance Technologies LLC increased its position in Castle Biosciences by 8.1% during the 1st quarter. Renaissance Technologies LLC now owns 532,800 shares of the company’s stock valued at $13,080,000 after buying an additional 39,700 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians make more informed decisions about cancer diagnosis and treatment. Its products use genomic and molecular information to assess disease characteristics, patient risk and likely outcomes.

The company’s portfolio includes DecisionDx-Melanoma, which helps assess the risk of metastasis in patients with cutaneous melanoma; DecisionDx-SCC, which evaluates metastatic risk in certain patients with cutaneous squamous cell carcinoma; and MyPath Melanoma, which assists in distinguishing benign from malignant melanocytic lesions.